Personalis to Announce Third Quarter 2022 Financial Results

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) will release its Q3 2022 financial results on November 2, 2022. The company will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and recent highlights. Interested parties can register for the call in advance, and a live webinar will be available on the company's website. Personalis is focused on advanced genomics for precision oncology, providing insights into cancer therapies and diagnostics through its NeXT Platform, which analyzes all human genes from a single sample.

Positive

• Upcoming release of Q3 2022 financial results according to schedule.
• Opportunity for investors to engage in a conference call for updates.

Negative

• None.

MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005051/en/

Investor Relations Contact for Personalis:

Caroline Corner

investors@personalis.com

www.westwicke.com

415-202-5678

Media Contact for Personalis:

Jennifer Temple

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.

FAQ

When will Personalis release their Q3 2022 financial results?

Personalis will release their Q3 2022 financial results on November 2, 2022.

What time is the Personalis Q3 2022 conference call?

The conference call for Q3 2022 will take place at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

How can I access the Personalis Q3 2022 conference call?

You can register for the conference call in advance using a link provided in their press release.

What is the focus of Personalis, Inc.?

Personalis focuses on advanced cancer genomics, providing precision therapies and diagnostics.